Quoin Pharmaceuticals, Ltd. financial data

Symbol
QNRX on Nasdaq
Industry
Pharmaceutical Preparations
Location
23 Hata'as Street, Kfar Saba, Israel
State of incorporation
Israel
Former names
Cellect Biotechnology Ltd. (to 10/15/2021), Cellect Biomed Ltd. (to 7/7/2016)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 330 % -16.6%
Debt-to-equity 93.4 % +15.8%
Return On Equity -112 % -4.68%
Return On Assets -57.7 % +2.22%

Shares

Label TTM Value / Value Unit Change %
Common Stock, Shares, Outstanding 3.98M shares -100%
Entity Public Float 5.8M USD +53.6%
Common Stock, Value, Issued 0 USD

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 2.95M USD -3.97%
Nonoperating Income (Expense) 660K USD +6.51%
Net Income (Loss) Attributable to Parent -8.28M USD +15%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.85M USD -40.2%
Assets, Current 13.2M USD -15.6%
Intangible Assets, Net (Excluding Goodwill) 533K USD -18.3%
Assets 14.1M USD -15.9%
Accounts Payable, Current 820K USD +15.8%
Accrued Liabilities, Current 1.39M USD -24.4%
Liabilities, Current 3.95M USD -10.5%
Other Liabilities, Noncurrent 2.62M USD -18.6%
Liabilities 6.58M USD -13.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 50.5M USD +19.7%
Retained Earnings (Accumulated Deficit) -50.5M USD -19.6%
Stockholders' Equity Attributable to Parent 7.48M USD -17.6%
Liabilities and Equity 14.1M USD -15.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.43M USD +17.9%
Net Cash Provided by (Used in) Financing Activities 5.33M USD -7.25%
Net Cash Provided by (Used in) Investing Activities -4.47M USD -27.9%
Common Stock, Shares Authorized 100M shares -100%
Common Stock, Shares, Issued 3.98M shares -100%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.85M USD -40.2%
Deferred Tax Assets, Valuation Allowance 6.22M USD +41.5%
Deferred Tax Assets, Gross 6.22M USD +41.5%
Deferred Tax Assets, Operating Loss Carryforwards 4.28M USD +28.3%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 58M USD +6.92%
Amortization of Intangible Assets 102K USD -2.26%
Share-based Payment Arrangement, Expense 1.18M USD +18.6%